Bruker (NASDAQ:BRKR) Given “Buy” Rating at Guggenheim

Guggenheim reiterated their buy rating on shares of Bruker (NASDAQ:BRKR) in a research report report published on Monday,Benzinga reports.

Other analysts also recently issued research reports about the company. Citigroup cut their target price on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Wells Fargo & Company lowered their price objective on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. The Goldman Sachs Group raised shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 target price on the stock in a report on Thursday, December 5th. UBS Group began coverage on shares of Bruker in a research note on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 price target for the company. Finally, Bank of America raised their price objective on Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, December 13th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $70.50.

Bruker Price Performance

Shares of NASDAQ:BRKR opened at $51.89 on Monday. The company’s fifty day moving average price is $56.63 and its 200-day moving average price is $59.95. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77. The firm has a market capitalization of $7.87 billion, a price-to-earnings ratio of 68.28, a PEG ratio of 2.16 and a beta of 1.16. Bruker has a one year low of $48.07 and a one year high of $94.86.

Bruker (NASDAQ:BRKR) last released its earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, beating analysts’ consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. On average, equities research analysts anticipate that Bruker will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Monday, March 17th will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.39%. The ex-dividend date is Monday, March 17th. Bruker’s payout ratio is 26.32%.

Hedge Funds Weigh In On Bruker

Hedge funds have recently made changes to their positions in the business. True Wealth Design LLC boosted its holdings in Bruker by 4,636.4% in the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 510 shares in the last quarter. Eagle Bay Advisors LLC boosted its stake in shares of Bruker by 2,324.1% during the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 674 shares in the last quarter. UMB Bank n.a. increased its position in shares of Bruker by 37.5% during the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock valued at $53,000 after buying an additional 248 shares during the period. GAMMA Investing LLC raised its stake in Bruker by 47.5% in the fourth quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company’s stock worth $75,000 after buying an additional 412 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its holdings in Bruker by 18.2% in the fourth quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company’s stock worth $75,000 after buying an additional 196 shares during the period. 79.52% of the stock is owned by hedge funds and other institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.